Overview

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Status:
Recruiting

Trial end date:
2027-12-03

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Adalimumab
Antibodies
Antibodies, Antinuclear